Biomolecular Life Holdings, Inc. Announces Completion of FINRA Name and Ticker Symbol Change to "BIOM" and Outlines Plan to Regain Fully Reporting Status Through Form 10 Registration

Miami, Florida — Tuesday, July 28, 2026 — Biomolecular Life Holdings, Inc. (OTC: BIOM) ("Biomolecular" or the "Company"), formerly known as SB Technology Holdings, Inc., today announced the completion of its name and ticker symbol change from "VGLS" to "BIOM" through the Financial Industry Regulatory Authority ("FINRA") and outlined a series of corporate actions the Company is undertaking to reestablish itself as a fully reporting public company, including the planned filing of a new Form 10 registration statement with the U.S. Securities and Exchange Commission (the "SEC").

Name and Ticker Symbol Change Completed Through FINRA

On June 15, 2026, the Company's Board of Directors and stockholders approved a change of the Company's name to Biomolecular Life Holdings, Inc. Articles of Amendment effecting the name change from SB Technology Holdings, Inc. were filed with the Florida Department of State on June 16, 2026, and the name change became legally effective upon filing. Following FINRA's review and processing of the Company's Issuer Company-Related Action Notification, the name change and voluntary ticker symbol change became effective in the marketplace on July 15, 2026, and the Company's common stock now trades under the symbol "BIOM" (CUSIP 91822T200).

The FINRA corporate action follows a series of structural steps completed over the past year, including a 1-for-20,000 reverse stock split. These actions align the Company's corporate identity, capitalization records, and public market presence under a single, current, and accurate structure.

Form 10 Registration Statement and Return to Fully Reporting Status

The Company is in the process of preparing a new Form 10 registration statement for filing with the SEC, having withdrawn its previously filed Form 10-12G in May 2026 in order to refile a complete and fully updated registration statement under the Company's new name and structure. Upon effectiveness, the Form 10 will register the Company's common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended, and Biomolecular will become a fully reporting company subject to the SEC's ongoing disclosure requirements, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. This will restore the full SEC reporting status the Company last maintained in 2018.

Management considers fully reporting status fundamental to the Company's commitment to transparency and to the standards shareholders should expect from a public issuer. The Form 10 process requires audited financial statements and comprehensive disclosure regarding the Company's history, capitalization, management, and governance. That work is well underway with the Company's auditors and securities counsel.

"Over the past several months we have methodically put our corporate affairs in order," said Jessika Contreras, Chief Executive Officer and President of Biomolecular Life Holdings, Inc. "We completed the reverse split and completed the name and ticker change through FINRA. The Form 10 filing is the next step. It will return this Company to fully reporting status and give our shareholders the transparency they deserve."

"Becoming a fully reporting company again is a deliberate choice about the kind of company we intend to be," added Ms. Contreras. "Shareholders should expect consistent disclosure, audited financial statements, and a management team that holds itself accountable. We are committed to meeting those standards and will update the market as each milestone is reached."

The Company will provide further updates as the Form 10 is filed and as the registration process advances.

About Biomolecular Life Holdings, Inc.

Biomolecular Life Holdings, Inc., formerly known as SB Technology Holdings, Inc., is a Florida corporation working to reestablish itself as an active, fully reporting public company through consistent disclosure, transparency, and operational discipline. The Company's common stock trades on the OTC market under the symbol "BIOM."

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, without limitation, statements regarding the Company's planned filing of a Form 10 registration statement, its intention to become a fully reporting company, and its ability to execute on its stated objectives. Actual results may differ materially from those expressed or implied due to a variety of risks and uncertainties, many of which are beyond the Company's ability to control, including the timing and outcome of regulatory review processes. The Company undertakes no obligation to update forward-looking statements except as required by law.

No Offer or Solicitation

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.

Company Contact

Biomolecular Life Holdings, Inc.
1395 Brickell Ave., Suite 800, Miami, FL 33131
Email: info@biomolecularlife.com
Phone: 877-646-4833
Website: www.biomolecularlifeholdingsinc.com